The Onion | America’s Finest News Source.
The Onion brings you all of the latest news, stories, photos, videos and more from America’s finest news source.
Related Articles
Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States | Annals of Internal Medicine
Background: Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities…
Inferior vena cava filters: a framework for evidence-based use
Venous thromboembolism (VTE) is a common cause of morbidity and mortality. Although most patients can be managed safely with anticoagulation, inferior vena cava filters (IVCFs)…
Aaron Logan, MD, PhD, MPhil on X: “#tandem24 #bmtsm Hamilton: CD19 therapy drives clonal hematopoiesis and cytopenias. 👀 Looked at 69 non-relapsed LBCL CART v 69 autoHCT pts finding higher risk of infections with CART https://t.co/uEuqODvNKW” / X
Don’t miss what’s happeningPeople on X are the first to know.#tandem24 #bmtsm Hamilton: CD19 therapy drives clonal hematopoiesis and cytopenias. Looked at 69 non-relapsed LBCL CART…
Paper: Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States
Program: Oral and Poster Abstracts Type: Oral Session: 904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders…
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis: Annals of Internal Medicine: Vol 0, No 0
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…
Paper: Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial
Program: Oral and Poster Abstracts Type: Oral Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment Hematology…
Paper: Metabolic Programming of Hematopoietic Stem Cell Function By Prenatal Folate
Program: General Sessions Session: Plenary Scientific Session Hematology Disease Topics & Pathways: Research, Fundamental Science, hematopoiesis, immunology, metabolism, Biological Processes, molecular biology, Metabolic Disorders, profiling,…
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis: Annals of Internal Medicine: Vol 0, No 0
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis: Annals of Internal Medicine: Vol 0, No 0
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…
Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis: Annals of Internal Medicine: Vol 0, No 0
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20%…